SecBot SecBot
Biotech Drug Report Generated Nov 7, 2026

BG-C477

ONC·BeOne Medicines Ltd.
MIXED
Drug Impact Rating3/10
Trial phase
Phase 1
Time to market
BG-C477 is in Phase 1 clinical development with no pivotal trial yet initiated. Even with an accelerated path, a potential approval would be several years away, likely 2029 or later.
Why 3/10
No hard dated binary catalyst (PDUFA, pivotal readout, or AdComm) is scheduled in the next ~12 months. The Phase 1a data was just presented at ESMO in October 2026. The Phase 1b expansion is ongoing with no specific topline readout date announced. BG-C477 is one of many early-stage programs at a large, multi-asset oncology company (BeOne has 35+ clinical and commercial assets), so even positive data would have limited stock impact. ImpactScore is 3 per the rubric: an early-stage drug with no near-term binary catalyst at a diversified company.
Actionable Insight MIXED

The next meaningful catalyst for BG-C477 will be further Phase 1b data, potentially at a major medical congress in 2027 (e.g., ASCO or ESMO), or an announcement of a Phase 2/pivotal trial initiation. Investors should watch for whether BeOne discloses a registrational path and timeline. The competitive landscape is also key: Merck KGaA's Precem-TcT is already in Phase 3, so BG-C477 needs to show differentiation in efficacy, safety, or target indications to carve out a commercial niche.

Price Chart

Loading chart...

Executive Summary

BG-C477 is an investigational antibody-drug conjugate (ADC) targeting CEACAM5 (CEA), developed by BeOne Medicines Ltd. (ticker: ONC, formerly BeiGene). It is in Phase 1a/b clinical development for advanced solid tumors. Initial Phase 1a data presented at ESMO 2026 showed a 60% confirmed response rate in CEA-high NSCLC patients with a favorable safety profile. However, the drug is early-stage (Phase 1), faces competition from Merck KGaA's Precem-TcT which is already in Phase 3, and represents a small part of BeOne's broad pipeline. No near-term binary catalyst is scheduled.

How It Works

BG-C477 is an antibody-drug conjugate (ADC), a type of targeted cancer therapy. It works like a guided missile: one part is an antibody that binds specifically to a protein called CEA (or CEACAM5) found at high levels on many cancer cells, and the other part is a chemotherapy payload (a topoisomerase 1 inhibitor) that kills the cell once delivered inside. The drug-to-antibody ratio is 8, meaning each antibody carries eight drug molecules.

Trial Status

BG-C477 is being studied in a global, multicenter, open-label Phase 1a/b first-in-human trial (NCT06596473) in patients with advanced solid tumors. The Phase 1a dose-escalation portion in non-small cell lung cancer (NSCLC) has completed enrollment. Initial results were presented at the ESMO 2026 Congress (October 23-27, 2026, Madrid). The Phase 1b dose-expansion portion is ongoing, evaluating BG-C477 alone and in combination with other anticancer agents including tislelizumab. The trial is expected to complete by December 31, 2027, with 310 patients planned across 54 sites globally.

The Two-Sided Case

▲ Bull Case4
At ESMO 2026, BG-C477 showed a 60.0% confirmed objective response rate (95% CI, 38.7-78.9) in CEA-high NSCLC patients (n=25) with a disease control rate of 92.0%, which is strong for a heavily pretreated population (median 3 prior lines of therapy).
The safety profile appears favorable with no grade 3 or higher interstitial lung disease or ocular events, differentiating it from some other ADCs.
BG-C477 is BeOne Medicines' first internally discovered ADC to achieve proof-of-concept, validating the company's internal ADC platform and potentially supporting a pipeline beyond this single asset.
The CEA biomarker strategy appears to enrich for responders, with the CEA-high subgroup showing meaningfully higher response rates than the overall NSCLC population (60% vs 34.9% at the April 2026 cutoff).
▼ Bear Case4
BG-C477 is still in early Phase 1 development with only 43 NSCLC patients reported; efficacy and durability data are preliminary and may not hold up in larger, more rigorous trials.
The CEACAM5 ADC space is increasingly competitive: Merck KGaA's precemtabart tocentecan (Precem-TcT) is already in Phase 3 for colorectal cancer, and M9140 (also Merck) is in Phase 1, both with similar TOP1i payload mechanisms.
BeOne Medicines is a large, diversified oncology company (35+ clinical and commercial assets) where BG-C477 represents a small, early-stage part of the pipeline; even positive data may have limited impact on the stock.
The earlier CEA-targeted ADC tusamitamab ravtansine (tusa rav) failed its Phase 3 trial, highlighting the historical difficulty of targeting this antigen effectively.

Upcoming Catalysts

  • Further Phase 1b dose-expansion data readouts (no specific date announced)
  • Potential initiation of a Phase 2 or pivotal study (timing not yet disclosed)
  • Additional data at future medical congresses (e.g., ASCO 2027)

Source Filing

The SecBot filing or press-release report that triggered this drug report:

BeOne Medicines Ltd. 8-K ONC ·Originating report

Sources · 13

Hover a chip for the title
1 beonemedinfo.com2 beonemedicines.com3 cancernetwork.com4 cancernetwork.com5 novapharmanews.com6 biospace.com7 businesswire.com8 clinicaltrials.gov9 synapse.patsnap.com10 emdserono.com11 vcbeathealth.com12 beonemedaffairs.com13 adisinsight.springer.com